AATF / Che-1 antibody (mAb) (Clone 1B2D8)

Host / Isotype

Rat / IgG2a

Reactivity

Human, Mouse

Applications

IF, WB

CloneNo.

1B2D8

Cat No : 61789,61790 61789

Synonyms



产品信息

Tested Applications IF, WB

Applications Validated by Active Motif: WB*: 2 - 4 ug/ml IF: 1:100 - 1:500 dilution For optimal results, primary antibody incubations should be performed at room temperature. The addition of 0.1% Tween 20 to all blocking solutions may also reduce background. Individual optimization may be required. *Note: many chromatin-bound proteins are not soluble in a low salt nuclear extract and fractionate to the pellet. Therefore, we recommend a High Salt / Sonication Protocol when preparing nuclear extracts for Western blot.

Tested Reactivity Human, Mouse
Host / Isotype Rat / IgG2a
Class Monoclonal
Type Antibody
Immunogen This antibody was raised against peptide comprising amino acids 1-39 of mouse AATF (Apoptosis-antagonizing transcription factor) (NP_062790).
Full Name AATF / Che-1 antibody (mAb) (Clone 1B2D8)
Synonyms
Molecular weight
GenBank accession numberNP_062790
RRIDAB_2793767
Purification Method Protein A Chromatography
Buffer Purified IgG in PBS with 30% glycerol and 0.035% sodium azide. Sodium azide is highly toxic.
Storage Some products may be shipped at room temperature. This will not affect their stability or performance. Avoid repeated freeze/thaw cycles by aliquoting items into single-use fractions for storage at -20°C for up to 2 years. Keep all reagents on ice when not in storage.

背景介绍

AATF/Che-1, or Apoptosis-antagonizing Transcription Factoris a key regulator of apoptosis through its interaction with MAP3K12 (DLK), as well as regulation of gene transcription and cell profileration through interaction with RNA polymerase II. AATF/Che-1 may promote cell proliferation by acting as a competitor of histone deacetylase 1 (HDAC1) interaction with the growth inhibiting protein pRb. AATF / Che-1 binding to pRb may displace HDAC1 from RB1/E2F complexes, leading to activation of E2F target genes and cell cycle progression.